David Y A Dadey1, Adrian Rodrigues2, Ghani Haider3, Erqi L Pollom4, John R Adler3, Anand Veeravagu3. 1. Department of Neurosurgery, Stanford University Medical Center, 453 Quarry Road, Stanford, CA, 94304, USA. dadeyd@stanford.edu. 2. School of Medicine, Stanford University, 291 Campus Drive, Stanford, CA, 94305, USA. 3. Department of Neurosurgery, Stanford University Medical Center, 453 Quarry Road, Stanford, CA, 94304, USA. 4. Department of Radiation Oncology, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA, 94305, USA.
Abstract
BACKGROUND: Stereotactic radiosurgery (SRS) to the surgical bed of resected brain metastases is now considered the standard of care due to its advantages over whole brain radiation therapy (WBRT). Despite the upward trend in SRS adoption since the 2000s, disparities have been reported suggesting that socio-economic factors can influence SRS utilization. OBJECTIVE: To analyze recent trends in SRS use and identify factors that influence treatment. METHODS: We conducted a retrospective cohort study with the Optum Commercial Claims and Encounters Database and included all patients from 2004 to 2021 who received SRS or WBRT within 60 days after resection of tumors metastatic to the brain. RESULTS: A total of 3495 patients met the inclusion and exclusion criteria. There were 1998 patients in the SRS group and 1497 patients in the WBRT group. SRS use now supersedes WBRT by a wide margin. Lung, breast and colon were the most common sites of primary tumor. Although we found no significant differences based on race among the treatment groups, patients with annual household income greater than $75,000 and those with some college or higher education are significantly more likely to receive SRS (OR 1.44 and 1.30; 95% CI 1.18-1.76 and 1.08-1.56; P = 0.001 and 0.005, respective). Patients with Elixhauser Comorbidity Index of three or more were significantly more likely to receive SRS treatment. CONCLUSION: The use of post-surgical SRS for brain metastasis has increased significantly over time, however education and income were associated with differential SRS utilization.
BACKGROUND: Stereotactic radiosurgery (SRS) to the surgical bed of resected brain metastases is now considered the standard of care due to its advantages over whole brain radiation therapy (WBRT). Despite the upward trend in SRS adoption since the 2000s, disparities have been reported suggesting that socio-economic factors can influence SRS utilization. OBJECTIVE: To analyze recent trends in SRS use and identify factors that influence treatment. METHODS: We conducted a retrospective cohort study with the Optum Commercial Claims and Encounters Database and included all patients from 2004 to 2021 who received SRS or WBRT within 60 days after resection of tumors metastatic to the brain. RESULTS: A total of 3495 patients met the inclusion and exclusion criteria. There were 1998 patients in the SRS group and 1497 patients in the WBRT group. SRS use now supersedes WBRT by a wide margin. Lung, breast and colon were the most common sites of primary tumor. Although we found no significant differences based on race among the treatment groups, patients with annual household income greater than $75,000 and those with some college or higher education are significantly more likely to receive SRS (OR 1.44 and 1.30; 95% CI 1.18-1.76 and 1.08-1.56; P = 0.001 and 0.005, respective). Patients with Elixhauser Comorbidity Index of three or more were significantly more likely to receive SRS treatment. CONCLUSION: The use of post-surgical SRS for brain metastasis has increased significantly over time, however education and income were associated with differential SRS utilization.
Authors: Jason P Sheehan; Inga Grills; Veronica L Chiang; Huamei Dong; Arthur Berg; Ronald E Warnick; Douglas Kondziolka; Brian Kavanagh Journal: J Neurosurg Date: 2018-12-21 Impact factor: 5.115
Authors: Giuseppe Minniti; Scott G Soltys; Lia M Halasz; John C Breneman; Michael Chan; Nadia N Laack; John P Kirkpatrick Journal: Int J Radiat Oncol Biol Phys Date: 2018-03-01 Impact factor: 7.038
Authors: Daniel M Trifiletti; Jason P Sheehan; Surbhi Grover; Sunil W Dutta; Chad G Rusthoven; Brian D Kavanagh; Arjun Sahgal; Timothy N Showalter Journal: J Clin Neurosci Date: 2017-08-31 Impact factor: 1.961
Authors: Siyu Shi; Navjot Sandhu; Michael C Jin; Elyn Wang; Joseph Abi Jaoude; Kirsten Schofield; Carrie Zhang; Elisa Liu; Iris C Gibbs; Steven L Hancock; Steven D Chang; Gordon Li; Melanie Hayden-Gephart; John R Adler; Scott G Soltys; Erqi L Pollom Journal: Int J Radiat Oncol Biol Phys Date: 2019-11-27 Impact factor: 7.038
Authors: Alexander L Chin; Gordon Li; Melanie Hayden Gephart; Navjot Sandhu; Seema Nagpal; Scott G Soltys; Erqi L Pollom Journal: World Neurosurg Date: 2020-09-21 Impact factor: 2.104
Authors: Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers Journal: Lancet Oncol Date: 2009-10-02 Impact factor: 41.316